Síndrome de Miller Fisher: efecto adverso de dosis de refuerzo para COVID-19

INTRODUCTION: The SARS-CoV-2 coronavirus has been a challenge for public health, establishing the vaccine as the best tool for its prevention. CLINICAL CASE: We present the case of a patient in whom Miller Fisher syndrome was documented after receiving her booster dose with the Oxford-AstraZeneca va...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz, María, Melendez, Miguel, Torres, Laura, Gutiérrez, Julian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Neurológica Argentina. Published by Elsevier España, S.L.U. 2022
Materias:
Caso Clínico
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477964/
http://dx.doi.org/10.1016/j.neuarg.2022.08.001
Descripción
Sumario:INTRODUCTION: The SARS-CoV-2 coronavirus has been a challenge for public health, establishing the vaccine as the best tool for its prevention. CLINICAL CASE: We present the case of a patient in whom Miller Fisher syndrome was documented after receiving her booster dose with the Oxford-AstraZeneca vaccine. CONCLUSION: At the moment, a causal relationship between vaccination against COVID-19 and the development of Miller Fisher syndrome cannot be established, but knowledge of this potential adverse effect is relevant for early diagnosis and timely treatment.

Ejemplares similares